Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters.
about
Respiratory viruses other than influenza virus: impact and therapeutic advancesAnimal models for SARS and MERS coronavirusesA new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivoImmunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccineAdvances in antivirals for non-influenza respiratory virus infections.A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice.Human CD4(+) memory T-lymphocyte responses to SARS coronavirus infection.Progress towards recombinant anti-infective antibodies.Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease.A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunityThe spike protein of SARS-CoV--a target for vaccine and therapeutic development.Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challengeAn immunosuppressed Syrian golden hamster model for SARS-CoV infection.A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo.Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV)Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.Synthetic reconstruction of zoonotic and early human severe acute respiratory syndrome coronavirus isolates that produce fatal disease in aged mice.Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoVStructural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challengeDevelopment of animal models against emerging coronaviruses: From SARS to MERS coronavirusA review of genetic methods and models for analysis of coronavirus-induced severe pneumonitis.Chronic beta-AR activation-induced calpain activation and impaired eNOS-Akt signaling mediates cardiac injury in ovariectomized female rats.The highly cited SARS research literature.Studies of severe acute respiratory syndrome coronavirus pathology in human cases and animal models.Animal models in virus research: their utility and limitations.The SARS-CoV ferret model in an infection-challenge study.Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapyLethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus.Animal models and vaccines for SARS-CoV infection.
P2860
Q24655957-8D966E25-7E15-4171-8D1A-5359989A2D58Q26799857-DF5449B2-F065-4FCA-B80C-75773A7026E6Q27490484-995B8076-5252-443A-A709-3DB1E9CCE9AAQ30430552-CE68C5FD-6888-4FEB-A1F6-06524FD6D222Q30457132-9EB9746B-FF48-4C16-A53A-3C77496B238BQ33269158-F549EA20-2E0C-4C66-97B0-94404F8FFFFBQ33293891-10FFF237-5424-4C02-80FA-D743F5E9AD3CQ33568256-B4673FD7-D13D-488D-BD80-2A546A397483Q33695621-199625D9-5711-436E-AD27-F6D33A7ADB36Q33904997-ECF9B809-E4AA-4CCA-9DF8-1A0E202486BAQ34015988-4E33FF1D-CB29-48F7-B236-B146D478467EQ34361120-C583EA6C-A6FB-4005-878B-97052D6E9B02Q34818143-14CDD261-619C-44DA-BE21-3EB2742ECCD7Q35635337-F388B437-F9CD-42C7-8DD3-18176CD5928AQ35740733-0B02F6AB-6092-40D9-9541-34B1406ADE5FQ35901171-B5B0954F-D0BB-4D2A-AA5B-BA9F6B73A511Q35914462-DA49C817-D9C0-425A-A8CC-7BBF4FF7086BQ36496355-0E3D6DAA-488A-46B5-A060-841D016D52BCQ36498144-66FB4526-6232-4955-8314-7BABCF695607Q36691163-86EA68FF-097C-47E3-89F3-28F89F3053A0Q36739375-88D00B35-58CF-4A27-AEF8-819D0B94CCBDQ37486435-B96991F3-BDF8-4C81-8A79-4109F6DEC374Q37760943-F4833C40-14CF-43EA-AB8D-53EE1DC60484Q37776085-0853F796-877F-4197-B052-9EC30A153A08Q38043556-4E5B269B-2C45-45C8-BBA8-6BAB57426871Q39370292-B5C4ADB3-C800-4344-A8D7-CEC93E98DF3CQ39727842-E2CD9139-A408-4551-9BFE-1100BE9D054AQ42020947-B066545B-E592-450E-A8C0-E394AE8F9BBEQ43152086-56F8BE98-0809-4738-ACB0-59A87694027F
P2860
Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Therapy with a severe acute re ...... den in golden Syrian hamsters.
@ast
Therapy with a severe acute re ...... den in golden Syrian hamsters.
@en
Therapy with a severe acute re ...... den in golden Syrian hamsters.
@nl
type
label
Therapy with a severe acute re ...... den in golden Syrian hamsters.
@ast
Therapy with a severe acute re ...... den in golden Syrian hamsters.
@en
Therapy with a severe acute re ...... den in golden Syrian hamsters.
@nl
prefLabel
Therapy with a severe acute re ...... den in golden Syrian hamsters.
@ast
Therapy with a severe acute re ...... den in golden Syrian hamsters.
@en
Therapy with a severe acute re ...... den in golden Syrian hamsters.
@nl
P2093
P50
P356
P1476
Therapy with a severe acute re ...... den in golden Syrian hamsters.
@en
P2093
Donna M Ambrosino
Elaine W Lamirande
Gregory J Babcock
Jeannette Guarner
John L Sullivan
Leatrice Vogel
Norman Hayes
Thomas C Greenough
William D Thomas
P304
P356
10.1086/500143
P407
P577
2006-01-27T00:00:00Z